Who Paid My Doc
Hugo Rivadeneyra Pasten
Endocrinology, Diabetes & Metabolism Ames, IA Medical Doctor
NPI 1962766980 CMS profile 3588397
1015 Duff Avenue, Ames, IA 50010
General payments
$254
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Hugo Rivadeneyra Pasten of Ames, IA is reported in the CMS Open Payments database as having received $254 across 15 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 23rd percentile of Endocrinology, Diabetes & Metabolism profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
6 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $56 | 3 | |
| 2024 | General | $17 | 1 | |
| 2023 | General | $19 | 1 | |
| 2022 | General | $15 | 1 | |
| 2021 | General | $67 | 4 | |
| 2020 | General | $79 | 5 |
Beside peers
- Hugo Rivadeneyra Pasten
- Endocrinology, Diabetes & Metabolism median
- Middle half of Endocrinology, Diabetes & Metabolism
- National median
In program year 2025, general payments to Hugo Rivadeneyra Pasten were reported at $56. Among 5,868 Endocrinology, Diabetes & Metabolism profiles paid that year, the median was $507 and the middle half received between $135 and $1,838.
Show as a table
| Year | Hugo Rivadeneyra Pasten | Endocrinology, Diabetes & Metabolism median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $494 | $123–$2,253 | $163 |
| 2020 | $79 | $335 | $85–$1,841 | $114 |
| 2021 | $67 | $398 | $88–$1,981 | $132 |
| 2022 | $15 | $364 | $88–$1,568 | $149 |
| 2023 | $19 | $420 | $113–$1,614 | $160 |
| 2024 | $17 | $440 | $121–$1,646 | $164 |
| 2025 | $56 | $507 | $135–$1,838 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 59 drugsPart D claims
4,864
Drug cost
$2,609,560
Branded share of claims
66.6%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Ozempic Semaglutide | Brand | 566 | $685,170 | |
| Jardiance Empagliflozin | Brand | 381 | $390,466 | |
| Tresiba Flextouch U-200 Insulin Degludec | Brand | 143 | $210,743 | |
| Humulin R U-500 Kwikpen Insulin Regular, Human | Brand | 18 | $149,654 | |
| Trulicity Dulaglutide | Brand | 116 | $138,176 | |
| Mounjaro Tirzepatide | Brand | 89 | $122,663 | |
| Humalog Kwikpen U-200 Insulin Lispro | Brand | 22 | $85,942 | |
| Basaglar Kwikpen U-100 Insulin Glargine,hum.Rec.Anlog | Brand | 145 | $76,659 | |
| Fiasp Flextouch Insulin Aspart (Niacinamide) | Brand | 53 | $66,482 | |
| Tresiba Flextouch U-100 Insulin Degludec | Brand | 106 | $65,107 |
The 10 drugs with the highest cost, of 59 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 6,527 Part D prescribers listed as Endocrinology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 59 billing codesPaid by Medicare
$204,239
Medicare patients
525
Services billed
7,356
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Diabetes | 56% | |
| Arthritis | 42% | |
| Chronic kidney disease | 35% | |
| Ischemic heart disease | 26% | |
| Depression | 24% | |
| Atrial fibrillation | 21% | |
| Osteoporosis | 21% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Injection, denosumab, 1 mg J0897 | Office | 32 | 3,180 | $65,462 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
15 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Related records
Endocrinology, Diabetes & Metabolism in Iowa
Practitioners in the same specialty and state, ranked by reported value.
All Endocrinology, Diabetes & Metabolism
Everyone recorded under this specialty, nationwide.
Doctors in Iowa
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.